| 1 |
33057388 | The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats. | 2020 |
3 |
| 2 |
29468921 | Cross-species comparison of the metabolism and excretion of selexipag. | 2019 Mar |
1 |
| 3 |
28277164 | Pharmacokinetics of the selective prostacyclin receptor agonist selexipag in rats, dogs and monkeys. | 2018 Feb |
2 |
| 4 |
29588339 | Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral Artery. | 2018 Jun |
3 |
| 5 |
27919660 | A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries. | 2017 Jan 15 |
2 |
| 6 |
22918043 | Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery. | 2012 Dec |
1 |
| 7 |
20660124 | Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function. | 2010 Oct |
3 |
| 8 |
17545310 | 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. | 2007 Sep |
1 |